Age features of collagen exchange markers in patients with heart failure with intermediate emission faction on the background of metabolic syndrome
- 作者: Osipova O.A1, Drapkina O.M2, Shepel R.N2, Gosteva E.V3, Godlevskaya O.M4, Belousova O.N1
-
隶属关系:
- Belgorod State National Research University
- National Medical Research Centre for Therapy and Preventive Medicine
- N.N. Burdenko Voronezh State Medical University
- Kharkov Medical Academy of Postgraduate Education
- 期: 卷 31, 编号 6 (2020)
- 页面: 39-43
- 栏目: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/114222
- DOI: https://doi.org/10.29296/25877305-2020-06-07
- ID: 114222
如何引用文章
详细
全文:
![受限制的访问](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
作者简介
O. Osipova
Belgorod State National Research University
Email: osipova@bsu.edu.ru
Professor; MD
O. Drapkina
National Medical Research Centre for Therapy and Preventive MedicineMD, Corresponding Member of the Russian Academy of Sciences Moscow
R. Shepel
National Medical Research Centre for Therapy and Preventive MedicineCandidate of Medical Sciences Moscow
E. Gosteva
N.N. Burdenko Voronezh State Medical UniversityCandidate of Medical Sciences
O. Godlevskaya
Kharkov Medical Academy of Postgraduate EducationCandidate of Medical Sciences Ukraine
O. Belousova
Belgorod State National Research UniversityCandidate of Medical Sciences
参考
- Осипова О.А. Нагибина А.И., Комисов А.А. и др. Патоморфологические механизмы регуляции образования миокардиального фиброза у больных хронической сердечной недостаточностью на фоне ишемической болезни сердца. Сердечная недостаточность. 2016; 17 (5): 357-64 doi: 10.18087/RHFJ.2016.5.2137
- Cheng J.M., Akkerhuis K.M., Meilhac O. et al. Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography. Arterioscler. Thromb. Vasc. Biol. 2014; 34 (5): 1078-84. doi: 10.1161/ATVBAHA.114.303486
- Ravi Kanth V.V., Nageshwar R. Role of matrix metalloproteinases in physiological processes and disease. Indian J. Med. Res. 2014; 140 (5): 585-7.
- Душина А.Г., Лопина Е.А., Либис Р.А. Особенности хронической сердечной недостаточности в зависимости от фракции выброса левого желудочка. Российский кардиологический журнал. 2019; 2: 7-11 https://doi.org/10.15829/1560-4071-2019-2-7-11
- Скородумова Е.Г., Костенко В.А., Скородумова Е.А. и др. Портрет пациента с промежуточной фракцией выброса левого желудочка на фоне острой декомпенсациии сердечной недостаточности. Вестник СЗГМУ им. И.И. Мечникова. 2018; 10 (2): 87-91 doi: 10.17816/mechnikov201810287-91
- Pascual-Figal D.A. Ferrero-Gregori A., Gomez-Otero I. et al. Mid-range left ventricular ejection fraction: clinical profile and cause of death in ambulatory patients with chronic heart failure. Int. J. Cardiol. 2017; 240: 265-70. DOI: 10.1016 /j.ijcard.2017.03.032
- Guisado-Espartero M.E., Salamanca-Bautista P., Aramburu-Bodas Ö. et al. Heart failure with mid-range ejection fraction in patients admitted to internal medicine departments: findings from the RICA registry. Int. J. Cardiol. 2018; 255: 124-8. DOI: 10.1016/ j.ijcard.2017.07.101
- Koh A.S., Tay W.T., Teng T.H.K. et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur. J. Heart Fail. 2017; 19: 1624-34. DOI: 10.1002 /ejhf.945
- Toba H., Lindsey M.L. Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly. Pharmacol. Ther. 2019; 193: 99-120. doi: 10.1016/j.pharmthera.2018.08.014
- Srivastava, P.K., Hsu, J.J., Ziaeian, B. et al. Heart Failure With Mid-range Ejection Fraction. Curr. Heart Fail Rep. 2020; 17 (1): 1-8. https://doi.org/10.1007/s11897-019-00451-0
- Osipova O.A., Plaksina K.G., Komisov A.A. et al. Pathogenetic mechanisms of participation of the intercellular matrix of the myocardium cardiac remodeling in with chronic heart failure. Cardiology. 2015; 22: 18.
- Осипова О.А., Плаксина К.Г., Комисов А.А. и др. Патогенетические механизмы участия межклеточного матрикса миокарда в ремоделировании сердца у больных хронической сердечной недостаточностью. Научные ведомости Белгородского государственного университета. Серия: Медицина. Фармация. 2015; 22 (219): 18-25
- Hopps E., Lo Presti R., Montana M. et al. Gelatinases and their tissue inhibitors in a group of subjects with metabolic syndrome. J. Investig. Med. 2013; 61 (6): 978-83. doi: 10.2310/JIM.0b013e318294e9da
- Bfaszczyk E, Gawlik A. Neurotrophins, VEGF and matrix metalloproteinases: new markers or causative factors of metabolic syndrome components? Pediatr. Endocrinol. Diab. Metabol. 2016; 22 (3): 125-31. doi: 10.18544/pedm-22.03.0060
- Spinale F.G., Coker M.L., Thomas C.V. et al. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure. Relation to ventricular and myocyte function. Circ. Res. 1998; 82: 482-95. doi: 10.1161/01.res.82.4.482
- Schwartzkopff B., Fassbach M., Pelzer B. et al. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur. J. Heart Fail. 2002; 4: 439-44. doi: 10.1016/s1388-9842(02)00092-2
- Lindsay M.M., Maxwell P., Dunn F.G. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension. 2002; 40: 136-41. doi: 10.1161/01.hyp.0000024573.17293.23
- Morishita T., Uzui H., Mitsuke Ya. et al. Association between matrix metalloproteinase-9 and worsening heart failure events in patients with chronic heart failure. ESC Heart Fail. 2017; 4: 321-30. doi: 10.1002/ehf2.12137
补充文件
![](/img/style/loading.gif)